DCC (32nd by MUFFINN yet below 7000th by the gene-centric methods in HNSC samples), a putative candidate tumor suppressor, is inactivated by promoter hypermethylation in head and neck cancer [53] and loss of PPM1A (23rd by MUFFINN yet below 5000th by the gene-centric methods in stomach adenocarcinoma (STAD) samples) expression enhances invasion and epithelial-to-mesenchymal transition in bladder cancer [54]. Here, DCC is linked to urinary bladder carcinoma.